Search

everythinglearnresearchcommunity

for

Search:↓

A 25-year-old is considering treatments for hair regrowth, including ketoconazole shampoo, 5% Minoxidil, Minoxidil with Tretinoin, and possibly ordering RU58841. They are hesitant about using Dutasteride or Finasteride due to perceived risks but are motivated to regrow hair to improve appearance due to visible veins from low body fat.

The user experienced significant hair growth and increased density after using 1.1mg finasteride for 4-5 weeks and switching from topical to oral minoxidil (3mg) for 3 weeks. They reported no shedding and were uncertain if the growth was due to the oral minoxidil or finasteride.

The user is considering adjusting tretinoin strength to enhance minoxidil effectiveness, questioning whether to use 0.025% or 0.01% instead of 0.05% due to increased hair shedding. They have been using finasteride, minoxidil, and Nizoral, and are contemplating reintroducing microneedling.

A 20-year-old male has been experiencing hair loss since age 16 and has tried various treatments including topical minoxidil, topical and oral finasteride, and oral dutasteride with minoxidil, but has not seen significant improvement. He is currently using 1.5mg dutasteride and 5mg oral minoxidil daily, along with derma penning, and is seeking advice on regrowing hair to avoid using hair fibers.

The user shared positive results after using 5% minoxidil foam nightly and dermastamping weekly for hair growth, noting significant progress after three months. They plan to add finasteride in the future but are currently avoiding it due to age.

The user, a 27-year-old male, has been treating early hair loss with topical finasteride and minoxidil, then switched to oral finasteride and dutasteride, but has seen no improvement and plans to add oral minoxidil. Despite treatment, hair loss has progressed from Norwood 1-1.5 to Norwood 3, with noticeable thinning, especially on the left side.

The user has been using finasteride for 2.5 years and topical minoxidil for 9 months with minimal regrowth and is considering trying dutasteride or other treatments like microneedling and Maxogen. They are hesitant about a hair transplant and are advised to consider additional treatments or supplements.

The conversation discusses using minoxidil and finasteride for hair loss, with concerns about hair damage from massaging minoxidil into the scalp. Users suggest gentle application to avoid breakage and note that shedding is common after starting finasteride.

The user experienced significant hair quality and thickness improvement using a daily topical treatment of 0.3% finasteride and 6% minoxidil, with noticeable regrowth in the last few months. Minoxidil can darken hair by increasing pigmentation.

The user discovered their previous hair loss medication was counterfeit and switched to Propecia, which significantly lowered their DHT levels. They plan to continue using Propecia and add oral Minoxidil to their routine for better results.

Oral minoxidil can cause cardiovascular issues, but an extended release formulation may reduce side effects like heart rate and blood pressure spikes. This new formulation offers a safer option for those who previously had to stop due to health concerns.

Poor gut health may contribute to hair loss and scalp inflammation, with treatments like finasteride, minoxidil, and Nizoral being used. Improving gut health and addressing inflammation might help alleviate symptoms.

The conversation is about switching from brand-name Avodart to generic Dutasmart for hair loss treatment, with concerns about shedding and side effects. The user also discusses using oral Minoxidil and plans to increase the dose for better results.

Topical finasteride concentrations are likely much higher than necessary for effective follicular DHT suppression, with current standards being 100-1000 times above the theoretical minimum. Lower concentrations (0.001-0.0025%) might still work locally while minimizing systemic exposure.

Microneedling, when combined with finasteride and topical minoxidil, can enhance hair regrowth for male pattern baldness, especially at the temples. Users report varying success with needle depths between 0.5mm and 1.5mm, with stamps preferred over rollers to minimize scalp damage.

A 22-year-old male experiencing hair thinning has been using topical finasteride and minoxidil since September 2024, with improvement except in the frontal/middle scalp area. He seeks advice on additional treatments and has started scalp massages.

A 24-year-old male has been using 1mg finasteride daily, 5% minoxidil twice a day, ketoconazole shampoo, and dermastamping for hair regrowth, noticing progress in crown thickness and some temple regrowth. He is considering adding oral minoxidil to enhance results but is concerned about potential side effects.

The user experienced significant hair regrowth using a regimen of 1 mg finasteride daily, minoxidil twice daily, ketoconazole shampoo weekly, dermastamping weekly, and tretinoin. They reported no side effects and emphasized the importance of committing to the treatment.

The user must stop minoxidil due to a heart murmur and is considering alternatives like nanoxidil or stemoxydine while continuing dutasteride. Suggestions include adding pyrilutamide and alfatradiol or switching to topical minoxidil at a lower concentration.

Clascoterone 5% topical solution is effective and safe for long-term use in treating male pattern hair loss. Cosmo Pharma aims for EU and US approval, with a potential US release in late 2027 or early 2028.

The user experienced significant hair regrowth over 8 months using finasteride, minoxidil, and a custom topical mix including progesterone, cortisone, and alpha 5 estradiol. They reported no side effects and noticed improvement around the third month.

A 49-year-old male switched from Finasteride to Dutasteride 2.5 mg daily, along with oral Minoxidil 5 mg, resulting in significant hair regrowth and stopping hair loss after six months. Despite initial side effects like adrenaline spikes and urinary issues, the user is satisfied with the results and plans to continue the treatment.

The user is using oral finasteride and minoxidil, microneedling, and plans to add topical minoxidil to boost hair growth. They are considering adding tretinoin but are unsure if it's necessary.

The user is frustrated with hair loss despite using finasteride and is considering a hairpiece as a solution. Suggestions include trying a buzz cut, considering dutasteride or oral minoxidil, and addressing potential dietary issues.

Hair cloning and new treatments like ET-02, Veradermics (vdphl01), and wound-induced hair neogenesis show promise but are not yet widely available. Current effective treatments include minoxidil, finasteride, and dutasteride, with early intervention being crucial for better outcomes.

Using spirulina and chlorella to boost ferritin and iron levels reduced hair shedding by more than half in a month. The user found these natural supplements more effective than regular iron tablets for hair growth.

PP405, a topical treatment, shows promise for hair growth by activating inactive follicles, with 66% of participants experiencing positive results. The treatment is well-tolerated and may proceed directly to Phase 3 trials, offering a potential alternative to minoxidil and finasteride.

A 21-year-old man experienced positive hair regrowth results after using a homemade topical solution containing 0.030% finasteride and 5% minoxidil for four months. He reported no side effects with the Trichosol-based solution, unlike previous issues with alcohol-based formulas.

A 19-year-old male experiencing hair loss is seeking advice on managing it without sexual side effects. He has used topical minoxidil and finasteride but experienced side effects, and is considering lifestyle changes to help slow hair loss.

Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.